Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
JNJ-7706621
150
CHF
CHF 150.00
In stock
SYN-1048-M0011 mgCHF 150.00
SYN-1048-M0055 mgCHF 251.00
SYN-1048-M01010 mgCHF 425.00
SYN-1048-M05050 mgCHF 999.00
SYN-1048-M100100 mgCHF 1'706.00

Product Details | |
---|---|
Synonyms | JNJ7706621 |
Product Type | Chemical |
Properties | |
Formula | C15H12F2N6O3S |
MW | 394.4 |
CAS | 443797-96-4 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO or ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: Aurora A - CDK7 - CDK5 - CDK4 - CDK2 | Kinase Group: Other | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | KDKUVYLMPJIGKA-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS |
![]() |
Product Specification Sheet | |
Datasheet |
![]() |
JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDK) and aurora kinases. It demonstrates highest potency on CDK1/2 with IC(50) values of 9nM and 4nM respectively. It shows more than 6-fold selectivity for CDK1/2 over CDK3/4/6.
Product References
- The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases: S. Emanuel, et al.; Cancer Res. 65, 9038 (2005)